Fig. 3. NE-induced translocation of cPLA₂ to the nuclear envelope depends on CaMKII. VSMCs were treated with the CaMKII inhibitor KN-93 (10 µM) or its vehicle (VEH), or CaMKII antisense oligonucleotide (5 µM) or its vehicle (lipofectamine; LIPO, 2 mg ml^-1). (A) cPLA₂ translocation to the nuclear envelope in cells exposed to 10 µM NE or its vehicle (V) was visualized by confocal microscopy (100x magnification). (B) Density of cPLA₂ fluorescence around the nuclear envelope (n=5). ^*Value significantly different from the corresponding value obtained with V of NE (P<0.05).